Neurocrine Biosciences Inc. (NB3)

Overview

Neurocrine Biosciences, Inc., a prominent entity in the pharmaceutical industry, dedicates its expertise to the discovery, development, and commercialization of medical treatments for a broad spectrum of neurological, neuroendocrine, and neuropsychiatric disorders. With a global operational footprint, the company serves both the United States and international markets, leveraging advanced science in its quest to improve patient outcomes. Since its inception in 1992, Neurocrine Biosciences has established a strong presence in the medical field, with its headquarters situated in San Diego, California. The company's commitment to research and development in challenging medical domains illustrates its pivotal role in the pharmaceutical landscape.

Products and Services

INGREZZA: A leading treatment developed by Neurocrine Biosciences for tardive dyskinesia and chorea associated with Huntington's disease, offering hope and relief to patients grappling with these difficult conditions.

ALKINDI: Specifically formulated for adrenal insufficiency, ALKINDI represents a vital treatment option for patients facing this challenging endocrine disorder.

Efmody Capsules: Address classic congenital adrenal hyperplasia, providing targeted therapy to manage this rare but impactful condition effectively.

Orilissa Tablets: These tablets are a revolutionary non-surgical solution for managing endometriosis, offering women non-invasive relief from the pain and symptoms associated with the condition.

Oriahnn Capsules: A novel treatment option to manage uterine fibroids, Oriahnn capsules contribute to reducing the heavy menstrual bleeding caused by fibroids in premenopausal women.

In addition to these marketed products, Neurocrine Biosciences has a robust pipeline of candidates in various stages of clinical development, targeting a range of complicated medical conditions:

• Valbenazine: Under investigation for treating dyskinetic cerebral palsy in both pediatric and adult patients, expanding its therapeutic implications beyond its current indications.
• NBI-921352: Aimed at addressing developmental and epileptic encephalopathy syndrome in a broad patient population.
• NBI-827104: Focuses on treating epileptic encephalopathy with continuous spike-and-wave during sleep, offering a potential breakthrough for this challenging condition.
• Various Additional Candidates: Spanning treatments for major depressive disorder, schizophrenia, congenital adrenal hyperplasia, and cognitive impairment related to schizophrenia, these candidates exemplify Neurocrine Biosciences' commitment to addressing a wide array of CNS indications.

Neurocrine Biosciences not only thrives through its internal pipeline but also collaborates extensively with other leading entities in the pharmaceutical industry. It has established license and collaboration agreements with Heptares Therapeutics Limited, Takeda Pharmaceutical Company Limited, Idorsia Pharmaceuticals Ltd, Xenon Pharmaceuticals Inc., Voyager Therapeutics, Inc., BIAL - Portela & Ca, S.A., Mitsubishi Tanabe Pharma Corporation, and AbbVie Inc. These partnerships enable the company to expand its reach, diversify its portfolio, and enhance its contribution to healthcare and medicine.